# Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma

> **NCT07628595** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 19 (estimated)

## Conditions studied

- Multiple Myeloma (MM)

## Interventions

- **DRUG:** RN9101 injection

## Key facts

- **NCT ID:** NCT07628595
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-11-01
- **Target enrollment:** 19 (ESTIMATED)
- **Last updated:** 2026-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07628595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07628595, "Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07628595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*